Aug 2026· Journal of the American Chemical Society· Vol 148 33, pp.
36006-36021
· 0 citations· 51 references
Medicine
TL;DR
Kinetic programming of PEG shedding is established as a design principle for dynamically regulating nanoparticle biointerfaces across distinct delivery routes across distinct delivery routes.
Abstract
Polyethylene glycol (PEG) can stabilize nanoparticles and facilitate transport across biological barriers, yet the same PEG layer suppresses cellular uptake─a trade-off known as the PEG dilemma. Current strategies seek to overcome this limitation by enabling PEG shedding in response to pathological biochemical cues, but their dependence on heterogeneous microenvironments limits predictability and cross-route applicability. Here, we report a thermoresponsive PEG shedding strategy based on PEG-lipid conjugates with oxanorbornadiene linkers that cleave at physiological temperature. By varying the linker structure, PEG shedding kinetics can be modulated over pharmacologically relevant time scales, enabling mRNA-lipid nanoparticles to undergo surface transitions from sterically shielded to cell-interactive states. In inhaled delivery, rapid PEG shedding after mucus traversal restored cellular uptake and markedly enhanced pulmonary mRNA expression, resulting in inhibition of pulmonary metastases. In systemic administration, intermediate PEG shedding preserved the circulation benefit of dense PEGylation while enabling subsequent intracellular delivery, leading to improved tumor expression and antitumor efficacy. These results establish kinetic programming of PEG shedding as a design principle for dynamically regulating nanoparticle biointerfaces across distinct delivery routes.
Key factors that link PEG-lipid composition and nanoparticle architecture to desorption kinetics and biological outcomes are identified and provide guidance for the design of PEGylated nanomaterials with improved control over interfacial stability, immune recognition, and functional performance.
Ethan P. Cisneros, Aadya S. Wijesekera, Lisa R. Volpatti· Small· 0 citations
It is demonstrated that controlled PEGylation can substantially reduce macrophage interactions and prolong encapsulin circulation in vivo, the first pharmacokinetic characterisation of an encapsulin nanocage.
Yi-Wen Ng, C. Rennie, India Boyton et al.· bioRxiv· 0 citations
A synthetic ionizable lipid with a dual pKa property that is retained in formulated LNPs is introduced and it is shown that after intravenous injection, these dual pKa LNPs produce lung‐selective mRNA expression with higher potency than a cationic lipid‐rich comparator while remaining well tolerated.
Seong Gi Lim, Min-Ju Lee, Yiming Wang et al.· Advancement of science· 0 citations
Lipid nanoparticles (LNPs) are clinically proven mRNA delivery vehicles, and repeated administration is often required to maintain therapeutic or prophylactic benefit. However, a single dose can provoke adaptive immune responses against polyethylene glycol (PEG), a polymeric excipient on the LNP surface. In this event,...
Mariah L. Arral, Namit Chaudhary, Katherine C. Fein et al.· Drug Delivery and Translatio...· 0 citations
A facile strategy by grafting glutamic acid-lysine (EK) peptides onto PEGylated phospholipid derivatives to assemble liposome (Lip)-based drug delivery systems is reported, offering a promising solution to the ABC effect in PEGylated liposomes.
Ning Wang, Zhi-Liang Gao, Meng-Qi Li et al.· ACS Applied Materials and In...· 1 citation